Newsletter | October 16, 2026

10.16.26 -- How Raw Material Decisions Can Impact Process Performance

SPONSOR

Strengthen drug product risk control

Explore solutions and best practices that support effective risk management across drug product manufacturing. Learn how a structured approach can help improve control, maintain quality, and support long-term operational confidence. View our new video.

How Perfusion In Seed Train Bioreactors Can Simplify Upstream Processes

Webinar | Cytiva

N-1 perfusion achieved approximately 95% viability while scaling from bench to production. See how this approach intensified seed trains.

 

A Comprehensive Solution With Targeted And Non-Targeted Approaches

Webinar | MilliporeSigma

Explore how non-targeted NGS and targeted molecular assays can work together during cell line characterization to provide broad virus detection while supporting evolving regulatory expectations.

How Raw Material Decisions Can Impact Process Performance

Video | Bioprocess Online

In this segment from the Bioprocess Online Live event, panelists discuss how early-stage raw material decisions impact later-stage manufacturing and process performance, as well as the specific trade-offs to consider when it comes to raw materials for clinical manufacturing.

Industry Trends: Connecting Quality, Manufacturing, And Asset Management

Webinar | MasterControl, Inc.

Master the shift to CSA and QMSR to reduce validation burdens. Learn to integrate systems and apply AI for predictive quality and operational excellence. Access the strategic roadmap today.

Transitioning From 2D To 3D: Getting Started With Spheroids

Webinar | LICORbio

As expectations for more physiologically relevant drug data rise, spheroids offer a practical path beyond 2D culture. Discover how to build reproducible 3D workflows and optimize key variables.

Single-Use Solutions For Critical Fluid Management Workflows

Video | Charter Medical

Delve into how single-use technologies support critical fluid management workflows across bioprocessing, cell and gene therapy, and blood management, enabling efficient handling, storage, and transfer.

SPONSOR

On Demand Webinar: Is CLD Slowing Your Pipeline? Accelerate Stable, High-Titer Clones in 14 Weeks

Cell line development is often a bottleneck in bioprocessing. Discover how to accelerate development by generating stable, high-producing CHO-K1 cell lines for mAbs, bispecific antibodies, and Fc-fusion proteins in under 14 weeks. We will highlight a platform that demonstrates scalability and stability for up to 100 generations, helping speed biotherapeutic development. Click here to learn more.

Connect With Bioprocess Online: